Search Results - "James, Leonard P."

Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes by OXNARD, Geoffrey R, BINSHENG ZHAO, SIMA, Camelia S, GINSBERG, Michelle S, JAMES, Leonard P, LEFKOWITZ, Robert A, PINGZHEN GUO, KRIS, Mark G, SCHWARTZ, Lawrence H, RIELY, Gregory J

“…We use changes in tumor measurements to assess response and progression, both in routine care and as the primary objective of clinical trials. However, the…”
Get full text

THE MYC/MAX/MAD NETWORK AND THE TRANSCRIPTIONAL CONTROL OF CELL BEHAVIOR by Grandori, Carla, Cowley, Shaun M, James, Leonard P, Eisenman, Robert N

“…The Myc/Max/Mad network comprises a group of transcription factors whose distinct interactions result in gene-specific transcriptional activation or…”
Get full text

Editorial Commentary: A Complex Network of Bony and Soft-Tissue Stabilizers—and Overall Limb Alignment—Determines Patellofemoral Stability by Leonard, James P

“…Patellofemoral stability is maintained through a complex network of static and dynamic soft-tissue stabilizers, the osseous structure of the patella and…”
Get full text

Editorial Commentary: Preoperative Exercise, Workers' Compensation, Diabetes, Lateral Extra-Articular Tenodesis, and Return to Sport Determine Patient Satisfaction After Anterior Cruciate Ligament Reconstruction by Leonard, James P

“…Patient-reported outcome measures (PROMs) have been developed and used as the primary determinant of successful patient-centered results. The patient…”
Get full text

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial by Shaw, Alice T, Felip, Enriqueta, Bauer, Todd M, Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F, Johnson, Melissa, Dietrich, Jorg, James, Leonard P, Clancy, Jill S, Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J

“…Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to…”
Get full text

Editorial Commentary: My Harvested Hamstring Autograft Is Too Small. Now What? by Leonard, James P

“…A harvested hamstring autograft that is too small is a technical challenge for an effective anterior cruciate ligament reconstruction. One potential solution…”
Get full text

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study by Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Felip, Enriqueta, Soo, Ross A, Camidge, D Ross, Chiari, Rita, Bearz, Alessandra, Lin, Chia-Chi, Gadgeel, Shirish M, Riely, Gregory J, Tan, Eng Huat, Seto, Takashi, James, Leonard P, Clancy, Jill S, Abbattista, Antonello, Martini, Jean-François, Chen, Joseph, Peltz, Gerson, Thurm, Holger, Ou, Sai-Hong Ignatius, Shaw, Alice T

“…Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study,…”
Get full text

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F by Shaw, Alice T, Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F, Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J, Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L, Schultz, Kate R, Logan, Jennifer, James, Leonard P, Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W, Engelman, Jeffrey A

“…A resistance mutation (C1156Y) developed in a woman with anaplastic lymphoma kinase ( ALK )-rearranged lung cancer who had a response to crizotinib. She then…”
Get full text

Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer by Chen, Joseph, Ruiz‐Garcia, Ana, James, Leonard P., Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer

“…Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of…”
Get full text

Response to “Lorlatinib Exposed: A Far from Optimal Dose” by Chen, Joseph, Ruiz‐Garcia, Ana, James, Leonard P., Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer

Get full text

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer by Zhao, Binsheng, James, Leonard P, Moskowitz, Chaya S, Guo, Pingzhen, Ginsberg, Michelle S, Lefkowitz, Robert A, Qin, Yilin, Riely, Gregory J, Kris, Mark G, Schwartz, Lawrence H

“…To evaluate the variability of tumor unidimensional, bidimensional, and volumetric measurements on same-day repeat computed tomographic (CT) scans in patients…”
Get full text

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants by Chen, Joseph, Xu, Huiping, Pawlak, Sylvester, James, Leonard P., Peltz, Gerson, Lee, Kimberly, Ginman, Katherine, Bergeron, Michelle, Pithavala, Yazdi K.

“…Introduction Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic…”
Get full text

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study by Jänne, Pasi A, Shaw, Alice T, Camidge, D Ross, Giaccone, Giuseppe, Shreeve, S Martin, Tang, Yiyun, Goldberg, Zelanna, Martini, Jean-François, Xu, Huiping, James, Leonard P, Solomon, Benjamin J

“…This phase I study investigated the activity of the irreversible pan-human epidermal growth factor receptor inhibitor dacomitinib in combination with the…”
Get more information

Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants by Chen, Joseph, Xu, Huiping, Pawlak, Sylvester, James, Leonard P., Peltz, Gerson, Lee, Kimberly, Ginman, Katherine, Bergeron, Michelle, Pithavala, Yazdi K.

“…In the original article, the reference 4 has been published and cited incorrectly…”
Get full text

Do Newer-Generation Bioabsorbable Screws Become Incorporated into Bone at Two Years After ACL Reconstruction with Patellar Tendon Graft?: A Cohort Study by Cox, Charles L, Spindler, Kurt P, Leonard, James P, Morris, Brent J, Dunn, Warren R, Reinke, Emily K

“…BACKGROUND:Bioabsorbable interference screws are used frequently for graft fixation in ACL (anterior cruciate ligament) reconstruction. The resorption…”
Get full text

Open surgical dislocation versus arthroscopic treatment of femoroacetabular impingement by Botser, Itamar B, Jackson, Timothy J, Smith, Thomas W, Leonard, James P, Stake, Christine E, Domb, Benjamin G

“…It is unclear if open surgical dislocation or arthroscopy of the hip is superior for the treatment of femoroacetabular impingement (FAI). We prospectively…”
Get full text

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion by Paik, Paul K., James, Leonard P., Riely, Gregory J., Azzoli, Christopher G., Miller, Vincent A., Ng, Kenneth K., Sima, Camelia S., Heelan, Robert T., Kris, Mark G., Moore, Erin, Rizvi, Naiyer A.

“…Purpose Paclitaxel is an effective therapy for patients with solid tumors. While the albumin-bound formulation eliminates the hypersensitivity reaction caused…”
Get full text

T1165 Use of Newer Agents in the Treatment of Gastric Adenocarcinoma by Somnay, Kaumudi, Kumar, Sandeep, James, Leonard P, Kaplan, Barry H

Get full text

Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non―Small Cell Lung Cancer1 by BINSHENG ZHAO, JAMES, Leonard P, MOSKOWITZ, Chaya S, PINGZHEN GUO, GINSBERG, Michelle S, LEFKOWITZ, RobertA, YILIN QIN, RIELY, GregoryJ, KRIS, Mark G, SCHWARTZ, Lawrence H

“…Our findings will help reveal variations in the unidimensional, bidimensional, and volumetric measurements on modern CT scans and thus be valuable in detecting…”
Get full text

A primary respiratory vs cardiac problem in a child—pediatric myocarditis by Allegretti, Paul J., Leonard, James P., Bzdusek, Jeffrey S.

Get full text